Soin Neuroscience, a biotech company based in Dayton, Ohio, USA, has received IRB (institutional review board) approval to commence a clinical case series to study spinal cord stimulator algorithms in patients who suffer from back pain.
Amol Soin, a pain management physician and chief executive officer of Soin Neuroscience, will be running the study in Dayton, USA. “I look forward to using Nuvectra’s Algovita, and its powerful spinal cord stimulator system to treat patients with back pain. We will be trialling waveforms that are unique to Nuvectra’s system. This is a small study that I hope will allow us to run additional larger studies. I think we can help a lot of people with back pain.”
Nuvectra has previously been recognised for its innovative Algovita SCS system. In 2017, Frost & Sullivan recognised Nuvectra with the 2017 North American New Product Innovation Award for its flagship product, the Algovita SCS System. This award was given based on analysis of the spinal cord stimulation market.
They said “SCS is fast becoming the non-drug alternative for chronic pain conditions, and Nuvectra’s commitment to advancing next-generation neurostimulation technologies makes it a crucial player in the market.”